(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
More parents refusing vitamin K shots for newborns, study finds- Aid sent by ambulance to Ukraine front line
- Palestinians tell BBC they were sexually abused in Israeli prisons
- AbbVie plans to build out its presence in obesity market
- What are the health benefits of whole milk for kids?
- Muslim nations condemn new Israeli death penalty law
- A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- Figure out How to Track and Anticipate Future Cd Rates
- Flu season is ramping up, and some experts are "pretty worried"
